59 results on '"Levy, Jerrold H"'
Search Results
2. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Preoperative Antithrombin Supplementation in Patients at Risk for Antithrombin Deficiency After Cardiac Surgery.
- Author
-
Moront MG, Woodward MK, Essandoh MK, Avery EG, Reece TB, Brzezinski M, Spiess B, Shore-Lesserson L, Chen J, Henriquez W, Barceló M, Despotis G, Karkouti K, Levy JH, Ranucci M, and Mondou E
- Subjects
- Adult, Aged, Antithrombins adverse effects, Cardiopulmonary Bypass adverse effects, Dietary Supplements, Double-Blind Method, Humans, Male, Prospective Studies, Treatment Outcome, Acute Kidney Injury etiology, Cardiac Surgical Procedures methods
- Abstract
Background: Antithrombin (AT) activity is reduced during cardiac operations with cardiopulmonary bypass (CPB), which is associated with adverse outcomes. Preoperative AT supplementation, to achieve >58% and <100% AT activity, may potentially reduce postoperative morbidity and mortality in cardiac operations with CPB. This prospective, multicenter, randomized, double-blind, placebo-controlled study was designed to evaluate the safety and efficacy of preoperative treatment with AT supplementation in patients at risk for low AT activity after undergoing cardiac surgery with CPB., Methods: A total of 425 adult patients were randomized (1:1) to receive either a single dose of AT (n = 213) to achieve an absolute increase of 20% above pretreatment AT activity or placebo (n = 212) before surgery. The study duration was approximately 7 weeks. The primary efficacy end point was the percentage of patients with any component of a major morbidity composite (postoperative mortality, stroke, acute kidney injury [AKI], surgical reexploration, arterial or venous thromboembolic events, prolonged mechanical ventilation, and infection) in the 2 groups. Secondary end points included AT activity, blood loss, transfusion requirements, duration of intensive care unit (ICU), and hospital stays. Safety was also assessed., Results: Overall, 399 patients (men, n = 300, 75.2%) with a mean (standard deviation [SD]) age of 66.1 (11.7) years, with the majority undergoing complex surgical procedures (n = 266, 67.9%), were analyzed. No differences in the percentage of patients experiencing morbidity composite outcomes between groups were observed (AT-treated 68/198 [34.3%] versus placebo 58/194 [29.9%]; P = .332; relative risk, 1.15). After AT infusion, AT activity was significantly higher in the AT group (108% [42-143]) versus placebo group (76% [40-110]), and lasted up to postoperative day 2. At ICU, the frequency of patients with AT activity ≥58% in the AT group (81.5%) was significantly higher ( P < .001) versus placebo group (43.2%). Secondary end point analysis did not show any advantage of AT over placebo group. There were significantly more patients with AKI ( P < .001) in the AT group (23/198; 11.6%) than in the placebo group (5/194, 2.6%). Safety results showed no differences in treatment-emergent adverse events nor bleeding events between groups., Conclusions: AT supplementation did not attenuate adverse postoperative outcomes in our cohort of patients undergoing cardiac surgery with CPB., Competing Interests: Conflicts of Interest: See Disclosures at the end of the article., (Copyright © 2022 International Anesthesia Research Society.)
- Published
- 2022
- Full Text
- View/download PDF
3. Thrombin Generation in Cardiac Versus Noncardiac Surgical Cohorts.
- Author
-
Ericksen WL, Levy JH, Kim ES, Nie L, Senzel LB, and Bennett-Guerrero E
- Subjects
- Aged, Anesthesia Recovery Period, Blood Coagulation Factors, Cohort Studies, Female, Hemodilution, Humans, Intensive Care Units, Male, Middle Aged, Prospective Studies, Thrombin analysis, Venous Thromboembolism blood, Cardiac Surgical Procedures, Surgical Procedures, Operative, Thrombin biosynthesis
- Abstract
Background: Bleeding can be a significant problem after cardiac surgery. As a result, venous thromboembolism (VTE) or anticoagulation or both following mechanical valve implantation are often delayed in these patients. The calibrated automated thrombin (CAT) generation assay has become the gold standard to evaluate thrombin generation, a critical step in clot formation independent of other hemostatic processes (eg, platelet activation, fibrin cross-linking, and fibrinolysis), and is increasingly used to examine thrombotic and hemorrhagic outcomes. No study has currently used this assay to compare the thrombin generation profiles of cardiac surgical patients to noncardiac surgical patients. We hypothesize that noncardiac patients may be less prone to postoperative changes in thrombin generation., Methods: A prospective, observational, cohort study was undertaken using blood samples from 50 cardiac and 50 noncardiac surgical patients preoperatively, immediately postoperatively, and on postoperative days 1 to 4. Platelet-poor plasma samples were obtained from patients preoperatively, on arrival to the postanesthesia care unit (PACU) or intensive care unit (ICU), and daily on postoperative days 1 to 4 if patients remained inpatient. Samples were evaluated for CAT measurements. Patient and surgical procedure characteristics were obtained from the electronic medical record., Results: The primary outcome variable, median endogenous thrombin potential (ETP), measured in nanomolar × minutes (nM × min), was decreased 100% in cardiac surgical versus 2% in noncardiac patients (P < .001). All parameters of thrombin generation were similarly depressed. Cardiac (versus noncardiac) surgical type was associated with -76.5% difference of percent change in ETP on multivariable regression analysis (95% confidence interval [CI], -87.4 to -65.5; P value <.001)., Conclusions: Cardiac surgical patients exhibit a profound decrease in thrombin generation postoperatively compared with noncardiac surgical patients evaluated by this study. Hemodilution and coagulation factor depletion likely contribute to this decreased thrombin generation after cardiac surgery., Competing Interests: Conflicts of Interest: See Disclosures at the end of the article., (Copyright © 2022 International Anesthesia Research Society.)
- Published
- 2022
- Full Text
- View/download PDF
4. The Contact Activation System: Problems and Paradoxes for Cardiac Anesthesiologists.
- Author
-
Sniecinski RM and Levy JH
- Subjects
- Cardiopulmonary Bypass, Heart, Humans, Anesthesiologists, Angioedemas, Hereditary
- Published
- 2020
- Full Text
- View/download PDF
5. In Response.
- Author
-
Raphael J, Mazer CD, Shore-Lesserson L, Bollen B, Levy JH, Schwann N, Subramani S, Schroeder A, Abdalla M, Ferreira R, Roman PE, Patel N, Welsby I, Greilich PE, Harvey R, Ranucci M, Heller LB, Boer C, Wilkey A, Hill SE, Nuttall GA, Palvadi RR, Patel PA, Wilkey B, Gaitan B, Hill SS, Kwa J, Klick J, Abernathy J, and Lau WT
- Subjects
- Hemorrhage, Hemostasis, Humans, Anesthesiologists, Cardiac Surgical Procedures
- Published
- 2020
- Full Text
- View/download PDF
6. Controlled Multifactorial Coagulopathy: Effects of Dilution, Hypothermia, and Acidosis on Thrombin Generation In Vitro.
- Author
-
Mitrophanov AY, Szlam F, Sniecinski RM, Levy JH, and Reifman J
- Subjects
- Adult, Aged, Blood Coagulation drug effects, Blood Coagulation physiology, Body Temperature, Female, Healthy Volunteers, Humans, Kinetics, Male, Middle Aged, Models, Biological, Partial Thromboplastin Time, Prothrombin Time, Young Adult, Acidosis blood, Blood Coagulation Disorders prevention & control, Hemodilution methods, Hypothermia, Induced, Thrombin biosynthesis
- Abstract
Background: Coagulopathy and hemostatic abnormalities remain a challenge in patients following trauma and major surgery. Coagulopathy in this setting has a multifactorial nature due to tissue injury, hemodilution, hypothermia, and acidosis, the severity of which may vary. In this study, we combined computational kinetic modeling and in vitro experimentation to investigate the effects of multifactorial coagulopathy on thrombin, the central enzyme in the coagulation system., Methods: We measured thrombin generation in platelet-poor plasma from 10 healthy volunteers using the calibrated automated thrombogram assay (CAT). We considered 3 temperature levels (31°C, 34°C, and 37°C), 3 pH levels (6.9, 7.1, and 7.4), and 3 degrees of dilution with normal saline (no dilution, 3-fold dilution, and 5-fold dilution). We measured thrombin-generation time courses for all possible combinations of these conditions. For each combination, we analyzed 2 scenarios: without and with (15 nM) supplementation of thrombomodulin, a key natural regulator of thrombin generation. For each measured thrombin time course, we recorded 5 quantitative parameters and analyzed them using multivariable regression. Moreover, for multiple combinations of coagulopathic conditions, we performed routine coagulation tests: prothrombin time (PT) and activated partial thromboplastin time (aPTT). We compared the experimental results with simulations using a newly developed version of our computational kinetic model of blood coagulation., Results: Regression analysis allowed us to identify trends in our data (P < 10). In both model simulations and experiments, dilution progressively reduced the peak of thrombin generation. However, we did not experimentally detect the model-predicted delay in the onset of thrombin generation. In accord with the model predictions, hypothermia delayed the onset of thrombin generation; it also increased the thrombin peak time (up to 1.30-fold). Moreover, as predicted by the kinetic model, the experiments showed that hypothermia increased the area under the thrombin curve (up to 1.97-fold); it also increased the height of the thrombin peak (up to 1.48-fold). Progressive acidosis reduced the velocity index by up to 24%; acidosis-induced changes in other thrombin generation parameters were much smaller or none. Acidosis increased PT by 14% but did not influence aPTT. In contrast, dilution markedly prolonged both PT and aPTT. In our experiments, thrombomodulin affected thrombin-generation parameters mainly in undiluted plasma., Conclusions: Dilution with normal saline reduced the amount of generated thrombin, whereas hypothermia increased it and delayed the time of thrombin accumulation. In contrast, acidosis in vitro had little effect on thrombin generation.
- Published
- 2020
- Full Text
- View/download PDF
7. Pathophysiological Response to Trauma-Induced Coagulopathy: A Comprehensive Review.
- Author
-
Duque P, Mora L, Levy JH, and Schöchl H
- Subjects
- Animals, Blood Platelets metabolism, Endothelium, Vascular metabolism, Endothelium, Vascular physiopathology, Fibrinogen metabolism, Fibrinolysis, Humans, Phenotype, Platelet Activation, Prognosis, Risk Factors, Thrombin metabolism, Thrombophilia blood, Thrombophilia physiopathology, Thrombophilia therapy, Wounds and Injuries blood, Wounds and Injuries physiopathology, Wounds and Injuries therapy, Blood Coagulation, Thrombophilia etiology, Wounds and Injuries complications
- Abstract
Hypercoagulability can occur after severe tissue injury, that is likely related to tissue factor exposure and impaired endothelial release of tissue plasminogen activator (tPA). In contrast, when shock and hypoperfusion occur, activation of the protein C pathway and endothelial tPA release induce a shift from a procoagulant to a hypocoagulable and hyperfibrinolytic state with a high risk of bleeding. Both thrombotic and bleeding phenotypes are associated with increased mortality and are influenced by the extent and severity of tissue injury and degree of hemorrhagic shock. Response to trauma is a complex, dynamic process in which risk can shift from bleeding to thrombosis depending on the injury pattern, hemostatic treatment, individual responses, genetic predisposition, and comorbidities. Based on this body of knowledge, we will review and consider future directions for the management of severely injured trauma patients.
- Published
- 2020
- Full Text
- View/download PDF
8. Tranexamic Acid for Acute Hemorrhage: When Is Enough Evidence Enough?
- Author
-
Faraoni D and Levy JH
- Subjects
- Hemorrhage, Humans, Antifibrinolytic Agents, Tranexamic Acid
- Published
- 2019
- Full Text
- View/download PDF
9. Ischemic Preconditioning and the Role of Antifibrinolytic Drugs: Translation From Bench to Bedside.
- Author
-
Quinones QJ and Levy JH
- Subjects
- Antifibrinolytic Agents, Ischemic Preconditioning, Tranexamic Acid
- Published
- 2018
- Full Text
- View/download PDF
10. Therapeutic Plasma Transfusion in Bleeding Patients: A Systematic Review.
- Author
-
Levy JH, Grottke O, Fries D, and Kozek-Langenecker S
- Subjects
- Clinical Trials as Topic methods, Hemorrhage diagnosis, Humans, Plasma Substitutes administration & dosage, Platelet Transfusion methods, Blood Component Transfusion methods, Hemorrhage therapy, Plasma
- Abstract
Plasma products, including fresh frozen plasma, are administered extensively in a variety of settings from massive transfusion to vitamin K antagonist reversal. Despite the widespread use of plasma as a hemostatic agent in bleeding patients, its effect in comparison with other available choices of hemostatic therapies is unclear. We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, PubMed Central, and databases of ongoing trials for randomized controlled trials that assessed the efficacy and/or safety of therapeutic plasma as an intervention to treat bleeding patients compared with other interventions or placebo. Of 1243 unique publications retrieved in our initial search, no randomized controlled trials were identified. Four nonrandomized studies described the effect of therapeutic plasma in bleeding patients; however, data gathered from these studies did not allow for comparison with other therapeutic interventions primarily as a result of the low number of patients and the use of different (or lack of) comparators. We identified two ongoing trials investigating the efficacy and safety of therapeutic plasma, respectively; however, no data have been released as yet. Although plasma is used extensively in the treatment of bleeding patients, evidence from randomized controlled trials comparing its effect with those of other therapeutic interventions is currently lacking.
- Published
- 2017
- Full Text
- View/download PDF
11. In Response.
- Author
-
Mitrophanov AY, Szlam F, Sniecinski RM, Levy JH, and Reifman J
- Published
- 2017
- Full Text
- View/download PDF
12. In Response.
- Author
-
Mitrophanov AY, Szlam F, Sniecinski RM, Levy JH, and Reifman J
- Published
- 2017
- Full Text
- View/download PDF
13. A Step Toward Balance: Thrombin Generation Improvement via Procoagulant Factor and Antithrombin Supplementation.
- Author
-
Mitrophanov AY, Szlam F, Sniecinski RM, Levy JH, and Reifman J
- Subjects
- Blood Coagulation Tests methods, Factor VIIa administration & dosage, Humans, Recombinant Proteins administration & dosage, Thrombin antagonists & inhibitors, Antithrombins administration & dosage, Models, Theoretical, Thrombin metabolism, Thromboplastin administration & dosage
- Abstract
Background: The use of prothrombin complex concentrates in trauma- and surgery-induced coagulopathy is complicated by the possibility of thromboembolic events. To explore the effects of these agents on thrombin generation (TG), we investigated combinations of coagulation factors equivalent to 3- and 4-factor prothrombin complex concentrates with and without added antithrombin (AT), as well as recombinant factor VIIa (rFVIIa), in a dilutional model. These data were then used to develop a computational model to test whether such a model could predict the TG profiles of these agents used to treat dilutional coagulopathy., Methods: We measured TG in plasma collected from 10 healthy volunteers using Calibrated Automated Thrombogram. TG measurements were performed in undiluted plasma, 3-fold saline-diluted plasma, and diluted plasma supplemented with the following factors: rFVIIa (group rFVIIa); factors (F)II, FIX, FX, and AT (group "combination of coagulation factors" [CCF]-AT); or FII, FVII, FIX, and FX (group CCF-FVII). We extended an existing computational model of TG to include additional reactions that impact the Calibrated Automated Thrombogram readout. We developed and applied a computational strategy to train the model using only a subset of the obtained TG data and used the remaining data for model validation., Results: rFVIIa decreased lag time and the time to thrombin peak generation beyond their predilution levels (P < 0.001) but did not restore normal thrombin peak height (P < 0.001). CCF-FVII supplementation decreased lag time (P = 0.034) and thrombin peak time (P < 0.001) and increased both peak height (P < 0.001) and endogenous thrombin potential (P = 0.055) beyond their predilution levels. CCF-AT supplementation in diluted plasma resulted in an improvement in TG without causing the exaggerated effects of rFVIIa and CCF-FVII supplementation. The differences between the effects of CCF-AT and supplementation with rFVIIa and CCF-FVII were significant for lag time (P < 0.001 and P = 0.005, respectively), time to thrombin peak (P < 0.001 and P = 0.004, respectively), velocity index (P < 0.001 and P = 0.019, respectively), thrombin peak height (P < 0.001 for both comparisons), and endogenous thrombin potential (P = 0.034 and P = 0.019, respectively). The computational model generated subject-specific predictions and identified typical patterns of TG improvement., Conclusions: In this study of the effects of hemodilution, CCF-AT supplementation improved the dilution-impaired plasma TG potential in a more balanced way than either rFVIIa alone or CCF-FVII supplementation. Predictive computational modeling can guide plasma dilution/supplementation experiments.
- Published
- 2016
- Full Text
- View/download PDF
14. Prothrombin Complex Concentrates for Bleeding in the Perioperative Setting.
- Author
-
Ghadimi K, Levy JH, and Welsby IJ
- Subjects
- Algorithms, Animals, Anticoagulants adverse effects, Blood Coagulation Factors adverse effects, Chemistry, Pharmaceutical, Clinical Protocols, Hemostatics adverse effects, Humans, Off-Label Use, Perioperative Care adverse effects, Postoperative Hemorrhage blood, Postoperative Hemorrhage etiology, Practice Guidelines as Topic, Risk Assessment, Risk Factors, Thromboembolism blood, Thromboembolism chemically induced, Treatment Outcome, Blood Coagulation drug effects, Blood Coagulation Factors therapeutic use, Blood Loss, Surgical prevention & control, Hemostatics therapeutic use, Perioperative Care methods, Postoperative Hemorrhage prevention & control
- Abstract
Prothrombin complex concentrates (PCCs) contain vitamin K-dependent clotting factors (II, VII, IX, and X) and are marketed as 3 or 4 factor-PCC formulations depending on the concentrations of factor VII. PCCs rapidly restore deficient coagulation factor concentrations to achieve hemostasis, but like with all procoagulants, the effect is balanced against thromboembolic risk. The latter is dependent on both the dose of PCCs and the individual patient prothrombotic predisposition. PCCs are approved by the US Food and Drug Administration for the reversal of vitamin K antagonists in the setting of coagulopathy or bleeding and, therefore, can be administered when urgent surgery is required in patients taking warfarin. However, there is growing experience with the off-label use of PCCs to treat patients with surgical coagulopathic bleeding. Despite their increasing use, there are limited prospective data related to the safety, efficacy, and dosing of PCCs for this indication. PCC administration in the perioperative setting may be tailored to the individual patient based on the laboratory and clinical variables, including point-of-care coagulation testing, to balance hemostatic benefits while minimizing the prothrombotic risk. Importantly, in patients with perioperative bleeding, other considerations should include treating additional sources of coagulopathy such as hypofibrinogenemia, thrombocytopenia, and platelet disorders or surgical sources of bleeding. Thromboembolic risk from excessive PCC dosing may be present well into the postoperative period after hemostasis is achieved owing to the relatively long half-life of prothrombin (factor II, 60-72 hours). The integration of PCCs into comprehensive perioperative coagulation treatment algorithms for refractory bleeding is increasingly reported, but further studies are needed to better evaluate the safe and effective administration of these factor concentrates.
- Published
- 2016
- Full Text
- View/download PDF
15. What Is the PROPPR Transfusion Strategy in Trauma Resuscitation?
- Author
-
Janelle GM, Shore-Lesserson L, Smith CE, Levy JH, and Shander A
- Subjects
- Blood Transfusion standards, Humans, Platelet Transfusion standards, Randomized Controlled Trials as Topic methods, Resuscitation standards, Blood Transfusion methods, Plasma, Platelet Transfusion methods, Resuscitation methods, Trauma Centers standards
- Published
- 2016
- Full Text
- View/download PDF
16. Factor concentrates for perioperative bleeding: old drugs with new approaches.
- Author
-
Welsby IJ and Levy JH
- Subjects
- Female, Humans, Male, Blood Coagulation drug effects, Blood Coagulation Factors therapeutic use, Coagulants therapeutic use, Endarterectomy adverse effects, Plasma, Postoperative Hemorrhage therapy, Pulmonary Artery surgery
- Published
- 2015
- Full Text
- View/download PDF
17. Development of a novel blood-sparing agent in cardiac surgery: do we need another agent?
- Author
-
Faraoni D and Levy JH
- Subjects
- Female, Humans, Male, Antifibrinolytic Agents pharmacokinetics, Cardiopulmonary Bypass, Coronary Artery Bypass, Serine Proteinase Inhibitors pharmacokinetics
- Published
- 2014
- Full Text
- View/download PDF
18. Extracorporeal membrane oxygenation in the adult: a review of anticoagulation monitoring and transfusion.
- Author
-
Esper SA, Levy JH, Waters JH, and Welsby IJ
- Subjects
- Adult, Blood Coagulation drug effects, Blood Coagulation physiology, Drug Monitoring, Extracorporeal Membrane Oxygenation adverse effects, Extracorporeal Membrane Oxygenation instrumentation, Hemorrhage physiopathology, Humans, Monitoring, Intraoperative, Anticoagulants pharmacology, Blood Transfusion, Extracorporeal Membrane Oxygenation methods
- Abstract
Extracorporeal membrane oxygenation (ECMO) is a method of life support to maintain cardiopulmonary function. Its use as a medical application has increased since its inception to treat multiple conditions including acute respiratory distress syndrome, myocardial ischemia, cardiomyopathy, and septic shock. While complications including neurological and renal injury occur in patients on ECMO, bleeding and coagulopathy are most common. ECMO is associated with an inflammatory response promoting a hypercoagulable state, requiring anticoagulation to avoid thromboembolism originating in the nonendothelial surfaced circuit. However, excessive anticoagulation may result in bleeding complications including intracerebral hemorrhage. Monitoring anticoagulation for ECMO has its origins in cardiopulmonary bypass for cardiac surgery; however, there is no ideal level of anticoagulation, no standardized method to monitor anticoagulation, nor are all centers standardized on what is used for anticoagulation. Multiple blood products are used in an effort to decrease bleeding in the setting of anticoagulation, often in the setting of recent surgery, and this leads to significant increases in cost for patients on ECMO and transfusion-related complications. In this review article, we discuss the evolution of the various modalities of ECMO, indications, contraindications, and complications. Furthermore, we review the different strategies for anticoagulation and treatment of coagulopathy while on ECMO. Finally, we discuss the cost of ECMO and associated blood product transfusion.
- Published
- 2014
- Full Text
- View/download PDF
19. A case series of recombinant platelet factor 4 for heparin reversal after cardiopulmonary bypass.
- Author
-
Demma L and Levy JH
- Subjects
- Adult, Aged, Blood Coagulation Factors analysis, Blood Coagulation Tests, Heparin Antagonists adverse effects, Humans, Leukocyte Count, Middle Aged, Platelet Count, Platelet Factor 4 adverse effects, Postoperative Complications drug therapy, Postoperative Complications mortality, Postoperative Hemorrhage drug therapy, Postoperative Hemorrhage mortality, Protamines therapeutic use, Recombinant Proteins adverse effects, Recombinant Proteins therapeutic use, Retrospective Studies, Thrombocytopenia chemically induced, Thrombocytopenia epidemiology, Thrombosis drug therapy, Thrombosis mortality, Cardiopulmonary Bypass mortality, Heparin Antagonists therapeutic use, Platelet Factor 4 therapeutic use
- Abstract
Background: Platelet factor 4 (PF4) is released by activated platelets and has a strong affinity for heparin. Recombinant PF4 (rPF4) has been previously considered as an alternative to protamine for heparin reversal. However, it has been demonstrated that antibodies directed against the PF4/heparin moiety are important in the pathophysiologic development of heparin-induced thrombocytopenia, a prothrombotic complication for which cardiac bypass patients are at increased risk., Methods: We retrospectively analyzed a case series from an open-label, comparative phase I-II study of rPF4 and protamine after cardiac surgery to determine the heparin-reversal activity of different doses of IV rPF4. Sixteen patients received rPF4, and 5 received protamine. Activated clotting time (ACT) was used to monitor heparin reversal, with reversal defined as ACT <150 seconds. Platelets, white blood cells, C3a, C5a, fibrinopeptide A, von Willebrand factor antigen, and prothrombin fragment 1.2 were monitored postoperatively as indicators of coagulation and inflammation., Results: Heparin reversal was successful by 10 minutes after administration of rPF4 as measured by ACT in all 16 patients. Specifically, a dose of 5 mg/kg rPF4 resulted in ACT <150 seconds after 5 minutes in 10 of 10 patients. For both treatment groups, there were no bleeding or thrombotic complications, no clinical thrombocytopenia after day 5, and no deaths within the 30-day study period., Conclusions: Our case series demonstrates that heparin anticoagulation was effectively reversed by the administration of rPF4 without serious complications. Additional studies are needed to further validate the safety and efficacy of exogenous rPF4 administration.
- Published
- 2012
- Full Text
- View/download PDF
20. Complement activation and cardiac surgery: a novel target for improving outcomes.
- Author
-
Stahl GL, Shernan SK, Smith PK, and Levy JH
- Subjects
- Animals, Humans, Inflammation Mediators physiology, Signal Transduction drug effects, Signal Transduction immunology, Treatment Outcome, Cardiac Surgical Procedures adverse effects, Cardiovascular Agents administration & dosage, Complement Activation drug effects, Complement Activation immunology, Drug Delivery Systems methods
- Abstract
Complement activation and the resulting inflammatory response is an important potential mechanism for multisystem organ injury in cardiac surgery. Novel therapeutic strategies using complement inhibitors may hold promise for improving outcomes for cardiac surgical patients by attenuating complement activation or its biologically active effector molecules. Recent clinical trials evaluating complement inhibitors have provided important data to further delineate the impact of complement activation and its inhibition on clinical outcomes. In this review we examine the role of complement activation and its inhibition as a therapeutic approach in cardiac surgery.
- Published
- 2012
- Full Text
- View/download PDF
21. The effects of MDCO-2010, a serine protease inhibitor, on activated clotting time in blood obtained from volunteers and cardiac surgical patients.
- Author
-
Kim H, Szlam F, Tanaka KA, van de Locht A, Ogawa S, and Levy JH
- Subjects
- Adult, Aged, Anticoagulants adverse effects, Antifibrinolytic Agents adverse effects, Cardiopulmonary Bypass, Diatomaceous Earth, Dose-Response Relationship, Drug, Drug Interactions, Drug Monitoring methods, Female, Heparin adverse effects, Humans, Kaolin, Male, Middle Aged, Monitoring, Intraoperative methods, Point-of-Care Systems, Predictive Value of Tests, Serine Proteinase Inhibitors adverse effects, Time Factors, Anticoagulants pharmacology, Antifibrinolytic Agents pharmacology, Blood Coagulation drug effects, Cardiac Surgical Procedures, Heparin pharmacology, Serine Proteinase Inhibitors pharmacology, Whole Blood Coagulation Time instrumentation
- Abstract
Background: The activated clotting time (ACT) is widely used for monitoring heparin anticoagulation during cardiac surgery. Celite-based ACT values are prolonged when aprotinin is administered. MDCO-2010, a novel serine protease inhibitor, is currently being evaluated as a possible alternative to aprotinin. Therefore, we evaluated the in vitro effects of this novel agent on ACT values using 3 different point-of-care instruments with kaolin or celite as an activator., Methods: The study was performed in 2 parts. In the first part, blood samples were obtained from 15 healthy volunteers. Samples were pipetted into small Eppendorf tubes and 2 concentrations of the MDCO-2010 (100 and 500 nM, final concentration) alone or with heparin (1.2 or 2.4 U/mL) were added. ACTs were measured using Helena (celite), Hemochron (kaolin), and Medtronic (kaolin) devices. In the second part of the study, blood samples were obtained intraoperatively, at 5 time points, from 15 patients undergoing cardiopulmonary bypass. MDCO-2010 at a final concentration of 100 or 500 nM was added and ACT testing was performed as before. Additional coagulation tests included prothrombin time, activated partial thromboplastin time, fibrinogen, antithrombin, prothrombin, and anti-Xa levels., Results: Addition of MDCO-2010 concentration-dependently prolonged ACTs in volunteers' and patients' blood samples regardless of the ACT activator or device used. In volunteer samples (no heparin) and in patient samples (baseline and intensive care unit) percent changes in ACTs due to MDCO-2010 were on average 3.1 ± 1.8 times higher (95% confidence interval 2.6-3.6; P < 0.001) for the celite-based Helena device compared with either Hemochron or Medtronic devices., Conclusion: MDCO-2010 causes less ACT prolongation with kaolin than with celite activation.
- Published
- 2012
- Full Text
- View/download PDF
22. Fibrinogen and hemostasis: a primary hemostatic target for the management of acquired bleeding.
- Author
-
Levy JH, Szlam F, Tanaka KA, and Sniecienski RM
- Subjects
- Animals, Blood Component Transfusion, Blood Loss, Surgical prevention & control, Factor VIII therapeutic use, Fibrinogen metabolism, Hemorrhage blood, Hemorrhage etiology, Hemostatics metabolism, Humans, Postoperative Hemorrhage blood, Postoperative Hemorrhage therapy, Treatment Outcome, Fibrinogen therapeutic use, Hemorrhage therapy, Hemostasis, Hemostatic Techniques, Hemostatics therapeutic use
- Abstract
Fibrinogen plays several key roles in the maintenance of hemostasis. Its cleavage by thrombin and subsequent polymerization to form fibrin strands provides the structural network required for effective clot formation. During cases of acute blood loss, attempts to maintain circulating volume and tissue perfusion often involve the infusion of crystalloids, colloids, and red blood cells. Intravascular volume resuscitation, although vital, frequently results in dilution of the remaining clotting factors and onset of dilutional coagulopathy. In such cases, fibrinogen is the first coagulation factor to decrease to critically low levels. There currently is a lack of awareness among physicians regarding the significance of fibrinogen during acute bleeding and, at many centers, fibrinogen is not monitored routinely during treatment. We reviewed current studies that demonstrate the importance of considering fibrinogen replacement during the treatment of acquired bleeding across clinical settings. If depleted, the supplementation of fibrinogen is key for the rescue and maintenance of hemostatic function; however, the threshold at which such intervention should be triggered is currently poorly defined. Although traditionally performed via administration of fresh frozen plasma or cryoprecipitate, the use of lyophilized fibrinogen (concentrate) is becoming more prevalent in some countries. Recent reports relating to the efficacy of fibrinogen concentrate suggest that it is a viable alternative to traditional hemostatic approaches, which should be considered. The prospective study of fibrinogen supplementation in acquired bleeding is needed to accurately assess the range of clinical settings in which this management strategy is appropriate, the most effective method of supplementation and a comprehensive safety profile of fibrinogen concentrate used for such an approach.
- Published
- 2012
- Full Text
- View/download PDF
23. Perioperative anaphylaxis and the United States perspective.
- Author
-
Levy JH and Castells MC
- Subjects
- Female, Humans, Male, Anaphylaxis epidemiology, Anesthesia adverse effects, Anesthetics adverse effects, Drug Hypersensitivity epidemiology
- Published
- 2011
- Full Text
- View/download PDF
24. Commentary: recombinant activated factor VII: the controversial conundrum regarding its off-label use.
- Author
-
Karkouti K and Levy JH
- Subjects
- Clopidogrel, Humans, Male, Recombinant Proteins therapeutic use, Ticlopidine adverse effects, Factor VIIa therapeutic use, Hemorrhage drug therapy, Hemostasis drug effects, Hemostatics therapeutic use, Platelet Aggregation Inhibitors adverse effects, Ticlopidine analogs & derivatives
- Published
- 2011
- Full Text
- View/download PDF
25. A diagnosis of heparin-induced thrombocytopenia with combined clinical and laboratory methods in cardiothoracic surgical intensive care unit patients.
- Author
-
Demma LJ, Winkler AM, and Levy JH
- Subjects
- Antibodies blood, Anticoagulants immunology, Biomarkers blood, Cardiopulmonary Bypass adverse effects, Chi-Square Distribution, Enzyme-Linked Immunosorbent Assay, Georgia, Heparin immunology, Humans, Platelet Count, Platelet Factor 4 immunology, Platelet Function Tests, Predictive Value of Tests, ROC Curve, Retrospective Studies, Risk Assessment, Risk Factors, Serotonin blood, Thrombocytopenia blood, Thrombocytopenia chemically induced, Thrombocytopenia immunology, Anticoagulants adverse effects, Cardiac Surgical Procedures adverse effects, Clinical Laboratory Techniques, Heparin adverse effects, Intensive Care Units, Thoracic Surgical Procedures adverse effects, Thrombocytopenia diagnosis
- Abstract
Background: Diagnosing postoperative heparin-induced thrombocytopenia (HIT) in cardiothoracic surgical patients is complicated because of the profound thrombocytopenia that occurs with cardiopulmonary bypass (CPB). CPB predisposes patients to develop a frequent incidence of antibodies directed against platelet factor 4 (PF4)/heparin complexes and HIT. The sensitivity of readily available antibody immunoassays is high, but specificity is quite low. The use of both a clinical probability score and rapid laboratory immunoassay has been shown to increase specificity, which is of particular importance in the CPB setting. Prompt diagnosis is crucial because cessation of heparin and treatment with alternative anticoagulation can reduce the risk of thromboembolic events., Methods: We retrospectively reviewed records from cardiothoracic surgical patients whose serum was tested with both the serotonin release assay (SRA) and the PF4/heparin immunoassay from January 2007 through December 2010. We assigned a high, intermediate, or low clinical "4Ts" probability score that quantifies thrombocytopenia, timing of platelet decrease, and thrombotic complications in each patient. We then compared the clinical score and the PF4/heparin immunoassay against the "gold standard" diagnostic test, the SRA., Results: The sensitivity and specificity for PF4/heparin optical density >0.40 were 100% and 26%, respectively. Sensitivity and specificity for the diagnosis of HIT with a combination of PF4/heparin optical density >0.40 and high/intermediate 4Ts score were 100% and 70%, respectively. The negative predictive value was 100% for low 4Ts score., Conclusions: We demonstrated that the use of the 4Ts clinical score combined with the PF4/heparin immunoassay for HIT diagnosis increases the sensitivity and specificity of HIT testing compared with the PF4/heparin immunoassay alone. Furthermore, with an intermediate 4Ts score and positive PF4/heparin antibody test, a confirmatory platelet activation assay such as the SRA is necessary. Physicians treating patients after cardiothoracic surgery should recognize the need for an antibody test and confirmation with a platelet activation assay with even moderate clinical probability of HIT.
- Published
- 2011
- Full Text
- View/download PDF
26. Does perioperative systolic blood pressure variability predict mortality after cardiac surgery? An exploratory analysis of the ECLIPSE trials.
- Author
-
Aronson S, Dyke CM, Levy JH, Cheung AT, Lumb PD, Avery EG, Hu MY, and Newman MF
- Subjects
- Aged, Cardiac Surgical Procedures adverse effects, Cardiac Surgical Procedures trends, Female, Humans, Male, Middle Aged, Perioperative Care trends, Postoperative Complications physiopathology, Prospective Studies, Survival Rate trends, Treatment Outcome, Blood Pressure physiology, Cardiac Surgical Procedures mortality, Perioperative Care mortality, Postoperative Complications mortality
- Abstract
Background: Few studies describe an association of perioperative blood pressure stability with postoperative outcome. We tested the hypothesis that systolic blood pressure (SBP) variability in patients undergoing cardiac surgery is associated with 30-day mortality., Methods: Perioperative blood pressure variability was evaluated in the 1512 patients who were randomized and had perioperative hypertension in the ECLIPSE trials. Blood pressure variability was assessed as the product of magnitude × duration of SBP excursions outside defined SBP ranges (area under the curve). SBP ranges were analyzed from 65 to 135 mm Hg intraoperatively and 75 to 145 mm Hg pre- or postoperatively, up to 105 to 135 mm Hg intraoperatively and 115 to 145 mm Hg pre- or postoperatively, with the narrower ranges defined by progressively increasing the lower SBP limit by 10 mm Hg increments. Multiple logistic regression was used to assess the association of blood pressure variability with 30-day mortality obtained from the primary ECLIPSE trial results., Results: Increased SBP variability outside a range of 75 to 135 mm Hg intraoperatively and 85 to 145 mm Hg pre- and postoperatively is significantly associated with 30-day mortality. The odds ratio was 1.16 (95% confidence interval, 1.04-1.30) for 30-day mortality risk per incremental SBP excursion of 60 mm Hg × min/h. The predicted probability of 30-day mortality increased for low-risk patients from 0.2% to 0.5%, and for high-risk patients from 42.4% to 60.7% if the area under the curve increased from 0 to 300 mm Hg × min/h., Conclusions: Perioperative blood pressure variability is associated with 30-day mortality in cardiac surgical patients, proportionate to the extent of SBP excursions outside the range of 75 to 135 mm Hg intraoperatively and 85 to 145 mm Hg pre- and postoperatively. Predicted mortality was greater for high-risk patients than for low-risk patients.
- Published
- 2011
- Full Text
- View/download PDF
27. Diagnosing heparin-induced thrombocytopenia in cardiac surgical patients: not as easy as you think.
- Author
-
Demma LJ and Levy JH
- Subjects
- Heparin blood, Humans, Thinking, Thrombocytopenia blood, Cardiac Surgical Procedures adverse effects, Heparin adverse effects, Thrombocytopenia chemically induced, Thrombocytopenia diagnosis
- Published
- 2011
- Full Text
- View/download PDF
28. Etiology and assessment of hypercoagulability with lessons from heparin-induced thrombocytopenia.
- Author
-
Sniecinski RM, Hursting MJ, Paidas MJ, and Levy JH
- Subjects
- Animals, Humans, Thrombocytopenia blood, Thrombocytopenia genetics, Thrombophilia blood, Thrombophilia genetics, Heparin adverse effects, Thrombocytopenia chemically induced, Thrombocytopenia diagnosis, Thrombophilia diagnosis, Thrombophilia etiology
- Abstract
Hypercoagulability, or thrombophilia, is a condition associated with an abnormally increased tendency toward blood clotting. Affected individuals are prone to developing venous or arterial thrombosis and often require thromboprophylaxis. Hypercoagulability can be generally classified as either an inherited or acquired condition. Patients with an inherited thrombophilia have genetic variances that alter the quality or quantity of proteins involved with hemostasis. Hypercoagulability may also be acquired and develop as an exaggeration of normal physiologic responses to major tissue injury, or an abnormal response to various prothrombotic clinical factors. Careful assessment for hypercoagulability is important because effective management strategies, often involving anticoagulation, may be available. Heparin-induced thrombocytopenia is an example of an acquired hypercoagulable state that has been well studied and, when recognized, responds to appropriate therapy. In this article, we review the etiology, risks, and assessment of thrombophilia, with emphasis on the clinical lessons learned from heparin-induced thrombocytopenia.
- Published
- 2011
- Full Text
- View/download PDF
29. Guidelines for perioperative blood transfusion and conservation in cardiac surgery: lessons and challenges.
- Author
-
Hessel EA 2nd and Levy JH
- Subjects
- Cooperative Behavior, Guideline Adherence, Health Care Surveys, Humans, Interdisciplinary Communication, Patient Care Team, Practice Guidelines as Topic, Research Design, Societies, Medical, Blood Loss, Surgical prevention & control, Blood Transfusion standards, Cardiac Surgical Procedures standards, Postoperative Hemorrhage prevention & control
- Published
- 2010
- Full Text
- View/download PDF
30. Activated clotting times, heparin responses, and antithrombin: have we been wrong all these years?
- Author
-
Levy JH and Sniecinski RM
- Subjects
- Blood Coagulation Tests standards, Blood Coagulation Tests trends, Heparin blood, Humans, Whole Blood Coagulation Time standards, Whole Blood Coagulation Time trends, Antithrombin III metabolism, Heparin therapeutic use
- Published
- 2010
- Full Text
- View/download PDF
31. The anticoagulant effect of protamine sulfate is attenuated in the presence of platelets or elevated factor VIII concentrations.
- Author
-
Bolliger D, Szlam F, Azran M, Koyama K, Levy JH, Molinaro RJ, and Tanaka KA
- Subjects
- Adult, Blood Platelets drug effects, Data Interpretation, Statistical, Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged, Prothrombin Time, Thrombelastography, Thrombin biosynthesis, Blood Platelets physiology, Factor VIII physiology, Heparin Antagonists pharmacology, Protamines pharmacology
- Abstract
Background: Protamine sulfate is the antidote for heparin, but in excess it exerts weak anticoagulation., Methods: We evaluated the effects of increasing protamine concentrations (0 to 24 microg/mL) on prothrombin time and diluted Russell's viper venom time measurements on thrombin generation in platelet-poor and platelet-rich plasma after activation by tissue factor or actin, and on thromboelastometry in platelet-poor plasma and whole blood from 6 healthy volunteers. The reversibility of excess protamine (24 microg/mL) by recombinant factor VIIa or factor VIII/von Willebrand factor concentrate was also tested., Results: Protamine prolonged prothrombin time and Russell's viper venom time, concentration dependently. Protamine also increased lag time and decreased peak of thrombin generation in platelet-poor plasma after tissue factor and actin activation. In platelet-rich plasma with platelets at 50 to 200 x 10(3)/microL, protamine (24 microg/mL) prolonged the lag time, but had no effect on peak thrombin generation. The addition of factor VIII/von Willebrand factor (1.5-3.0 U/mL) to platelet-poor plasma with protamine (24 microg/mL) decreased lag time and increased peak thrombin generation with actin activation. A therapeutic concentration of recombinant factor VIIa (60 nM) only affected the lag time of thrombin generation triggered with actin. In agreement, protamine increased coagulation time evaluated by thromboelastometry significantly more in platelet-poor plasma than in whole blood., Conclusions: We demonstrated that protamine affects the propagation of thrombin generation, which is partially reversed by platelets or increased factor VIII/von Willebrand factor concentrations. The present data suggest that excess protamine might potentially increase bleeding in the case of severe thrombocytopenia or low factor VIII.
- Published
- 2010
- Full Text
- View/download PDF
32. Hereditary angioedema: current and emerging treatment options.
- Author
-
Levy JH, Freiberger DJ, and Roback J
- Subjects
- Adult, Angioedemas, Hereditary diagnosis, Angioedemas, Hereditary etiology, Angioedemas, Hereditary prevention & control, Child, Humans, Perioperative Care, United States, United States Food and Drug Administration, Angioedemas, Hereditary therapy
- Abstract
Angioedema can result from allergic, hereditary, and acquired conditions. Hereditary angioedema (HAE) attacks are disabling at the time of occurrence and can be life threatening; they often result in hospitalization and intensive care unit admission. Although there are several variants of HAE, they share a final common pathway: unopposed activation of multiple kinins and mediators including kallikrein and bradykinin. This leads to increased vascular permeability, which in turn produces the edema after which the condition is named. Older treatment options licensed in the United States, anabolic steroids and antifibrinolytics, have troublesome side effect profiles and may not reverse a severe acute attack. In Europe, C1 esterase inhibitor (C1-INH) concentrates have been used since 1974 for both preventing and terminating attacks. Two of these have now been licensed in the United States for use in HAE patients, one for prophylaxis and the other for treating acute abdominal and facial HAE attacks. The first kinin pathway modulator, ecallantide, has also been licensed recently in the United States for treating HAE attacks. The objective of this article is to describe HAE and review the available options for managing patients, as well as different drugs currently under investigation. Specific attention is given to the perioperative management of patients with HAE.
- Published
- 2010
- Full Text
- View/download PDF
33. Multidisciplinary approach to the challenge of hemostasis.
- Author
-
Levy JH, Dutton RP, Hemphill JC 3rd, Shander A, Cooper D, Paidas MJ, Kessler CM, Holcomb JB, and Lawson JH
- Subjects
- Blood Coagulation Disorders diagnosis, Blood Coagulation Disorders etiology, Blood Loss, Surgical prevention & control, Cardiac Surgical Procedures, Clinical Trials as Topic, Endothelium, Vascular physiology, Hemorrhage etiology, Hemostatic Techniques, Hemostatics therapeutic use, Humans, Wounds and Injuries complications, Blood Coagulation Disorders therapy, Hemorrhage therapy, Hemostasis physiology
- Abstract
A multidisciplinary panel consisting of experts chosen by the 2 chairs of the group representing experts in anesthesiology, blood banking, hematology, critical care medicine, and various surgical disciplines (trauma, cardiac, pediatric, neurologic, obstetrics, and vascular) convened in January 2008 to discuss hemostasis and management of the bleeding patient across different clinical settings, with a focus on perioperative considerations. Although there are many ways to define hemostasis, one clinical definition would be control of bleeding without the occurrence of pathologic thrombotic events (i.e., when balance among procoagulant, anticoagulant, fibrinolytic, and antifibrinolytic activities is achieved). There are common hemostatic challenges that include lack of scientific evidence and standardized guidelines for the use of therapeutic drugs, need for reliable and rapid laboratory tools for measuring hemostasis, and individual variability. Clinically meaningful and accurate real-time laboratory data reflecting a patient's hemostatic status are needed to guide treatment decisions. Current available routine laboratory tests of hemostasis (e.g., platelet count, prothrombin time/international normalized ratio, and activated partial thromboplastin time) do not reflect the complexity of in vivo hemostasis and can mislead the clinician. Although point-of-care coagulation monitoring tests including measures of thromboelastography/elastometry provide insight into overall hemostatic status, they are time-consuming to perform, complex to interpret, and require trained personnel. There is a particular need to develop laboratory tests that can measure the effects of anticoagulant and antiplatelet agents for individual patients, predict bleeding complications, and guide therapy when and if treatment with blood products or pharmacologic drugs is required. Formation of an organization comprised of specialists who treat bleeding patients will foster multidisciplinary collaborations and promote discussions of the current state of hemostasis treatment and future priorities for hemostasis research. Controlled trials with clinically meaningful end points and suitable study populations, as well as observational studies, investigator-initiated studies, and large registry and database studies are essential to answer questions in hemostasis. Because of the complexities of maintaining hemostatic balance, advances in hemostasis research and continuing communication across specialties are required to improve patient care and outcomes.
- Published
- 2010
- Full Text
- View/download PDF
34. Blood coagulation: hemostasis and thrombin regulation.
- Author
-
Tanaka KA, Key NS, and Levy JH
- Subjects
- Blood Coagulation Tests, Endothelium, Vascular drug effects, Endothelium, Vascular metabolism, Fibrinolysis drug effects, Humans, Perioperative Care, Postoperative Hemorrhage blood, Postoperative Hemorrhage etiology, Protein C metabolism, Risk Assessment, Risk Factors, Thrombin antagonists & inhibitors, Thrombomodulin blood, Thrombosis blood, Blood Coagulation drug effects, Blood Loss, Surgical prevention & control, Fibrinolytic Agents adverse effects, Hemostatic Techniques, Postoperative Hemorrhage prevention & control, Thrombin metabolism, Thrombosis prevention & control
- Abstract
Perioperative bleeding is a major challenge particularly because of increasing clinical use of potent antithrombotic drugs. Understanding current concepts of coagulation is important in determining the preoperative bleeding risk of patients, and in managing hemostatic therapy perioperatively. The serine protease thrombin plays pivotal roles in the activation of additional serine protease zymogens (inactive enzymatic precursors), cofactors, and cell-surface receptors. Thrombin generation is closely regulated to locally achieve rapid hemostasis after injury without causing uncontrolled systemic thrombosis. During surgery, there are major disturbances in coagulation and inflammatory systems because of hemorrhage/hemodilution, blood transfusion, and surgical stresses. Postoperative bleeding often requires allogeneic blood transfusions, which support thrombin generation and hemostasis. However, procoagulant activity and inflammation are increased postoperatively; thus, antithrombotic therapy may be required to prevent perioperative thrombotic complications. There have been significant advances in the management of perioperative hemostasis and thrombosis because of the introduction of novel hemostatic and antithrombotic drugs. However, a limitation of current treatment is that conventional clotting tests do not reflect the entire physiological processes of coagulation making optimal pharmacologic therapy difficult. Understanding the in vivo regulatory mechanisms and pharmacologic modulation of thrombin generation may help control bleeding without potentially increasing prothrombotic risks. In this review, we focus on the regulatory mechanisms of hemostasis and thrombin generation using multiple, simplified models of coagulation.
- Published
- 2009
- Full Text
- View/download PDF
35. Anticoagulation and reversal paradigms: is too much of a good thing bad?
- Author
-
Levy JH and Tanaka KA
- Subjects
- Drug Hypersensitivity, Heparin adverse effects, Heparin therapeutic use, Heparin Antagonists adverse effects, Homeostasis drug effects, Humans, Protamines adverse effects, Thrombelastography, Anticoagulants adverse effects, Anticoagulants antagonists & inhibitors, Heparin Antagonists therapeutic use, Protamines therapeutic use
- Published
- 2009
- Full Text
- View/download PDF
36. The ECLIPSE trials: comparative studies of clevidipine to nitroglycerin, sodium nitroprusside, and nicardipine for acute hypertension treatment in cardiac surgery patients.
- Author
-
Aronson S, Dyke CM, Stierer KA, Levy JH, Cheung AT, Lumb PD, Kereiakes DJ, and Newman MF
- Subjects
- Acute Disease, Aged, Aged, 80 and over, Antihypertensive Agents adverse effects, Blood Pressure drug effects, Calcium Channel Blockers adverse effects, Female, Humans, Hypertension physiopathology, Intraoperative Complications drug therapy, Male, Nicardipine adverse effects, Nicardipine therapeutic use, Nitroglycerin adverse effects, Nitroglycerin therapeutic use, Nitroprusside adverse effects, Nitroprusside therapeutic use, Perioperative Care, Postoperative Complications drug therapy, Preoperative Care, Pyridines adverse effects, Antihypertensive Agents therapeutic use, Calcium Channel Blockers therapeutic use, Cardiac Surgical Procedures, Hypertension drug therapy, Pyridines therapeutic use
- Abstract
Background: Acute hypertension during cardiac surgery can be difficult to manage and may adversely affect patient outcomes. Clevidipine is a novel, rapidly acting dihydropyridine L-type calcium channel blocker with an ultrashort half-life that decreases arterial blood pressure (BP). The Evaluation of CLevidipine In the Perioperative Treatment of Hypertension Assessing Safety Events trial (ECLIPSE) was performed to compare the safety and efficacy of clevidipine (CLV) with nitroglycerin (NTG), sodium nitroprusside (SNP), and nicardipine (NIC) in the treatment of perioperative acute hypertension in patients undergoing cardiac surgery., Methods: We analyzed data from three prospective, randomized, open-label, parallel comparison studies of CLV to NTG or SNP perioperatively, or NIC postoperatively in patients undergoing cardiac surgery at 61 medical centers. Of the 1964 patients enrolled, 1512 met postrandomization inclusion criteria of requiring acute treatment of hypertension based on clinical criteria. The patients were randomized 1:1 for each of the three parallel comparator treatment groups. The primary outcome was the incidence of death, myocardial infarction, stroke or renal dysfunction at 30 days. Adequacy and precision of BP control was evaluated and is reported as a secondary outcome., Results: There was no difference in the incidence of myocardial infarction, stroke or renal dysfunction for CLV-treated patients compared with the other treatment groups. There was no difference in mortality rates between the CLV, NTG or NIC groups. Mortality was significantly higher, though, for SNP-treated patients compared with CLV-treated patients (P=0.04). CLV was more effective compared with NTG (P=0.0006) or SNP (P=0.003) in maintaining BP within the prespecified BP range. CLV was equivalent to NIC in keeping patients within a prespecified BP range; however, when BP range was narrowed, CLV was associated with fewer BP excursions beyond these BP limits compared with NIC., Conclusions: CLV is a safe and effective treatment for acute hypertension in patients undergoing cardiac surgery.
- Published
- 2008
- Full Text
- View/download PDF
37. HIT happens: diagnosing and evaluating the patient with heparin-induced thrombocytopenia.
- Author
-
Greinacher A and Levy JH
- Subjects
- Antibody Formation, Anticoagulants immunology, Cardiac Surgical Procedures adverse effects, Child, Heparin immunology, Humans, Infant, Newborn, Platelet Factor 4 immunology, Reoperation, Thrombocytopenia diagnosis, Anticoagulants adverse effects, Heparin adverse effects, Thrombocytopenia chemically induced
- Published
- 2008
- Full Text
- View/download PDF
38. Antithrombin deficiency increases thrombin activity after prolonged cardiopulmonary bypass.
- Author
-
Sniecinski R, Szlam F, Chen EP, Bader SO, Levy JH, and Tanaka KA
- Subjects
- Aged, Female, Humans, Male, Middle Aged, Thrombosis blood, Time Factors, Antithrombins deficiency, Blood Coagulation, Cardiac Surgical Procedures, Cardiopulmonary Bypass adverse effects, Circulatory Arrest, Deep Hypothermia Induced adverse effects, Thrombin metabolism, Thrombosis etiology, Transfusion Reaction
- Abstract
Background: Antithrombin (AT) levels decrease during cardiopulmonary bypass (CPB), particularly when combined with deep hypothermic circulatory arrest (DHCA). Low AT levels might lead to imbalance of pro- and anticoagulant factors promoting systemic thrombotic events. We hypothesized that low levels of AT might lead to increased in vitro thrombin generation when procoagulant factors are added to the patient's plasma after CPB., Methods: Blood samples were obtained before heparinization and after separation from CPB from five patients undergoing cardiac surgery with DHCA. AT levels were determined by chromogenic assay and expressed as a percent of normal activity. The balance between procoagulant and anticoagulant elements was manipulated in the patients' plasma by adding normal donor plasma, AT-deficient plasma, or purified AT. The Thrombinoscope system was used to evaluate thrombin generation with and without AT supplementation., Results: AT levels (median, range) were 82.0% (71.0, 109) and 37.0% (34.0, 41.0) of normal before and after separation from CPB, respectively (P < 0.05). Peak thrombin generation (median, range) was 56.6 nM (42.1, 61.0) in plasma after CPB, and it remained at 61.1 nM (54.9, 64.5) when a donor plasma with normal AT (105%) was added. When AT-deficient plasma was added to the patient's plasma, peak thrombin generation (median, range) was increased from 56.6 nM (42.0, 61.0) to 117 nM (95.0, 188) (P < 0.05 versus control). After the addition of purified AT, the peak thrombin generation was reduced to 12.2 nM (9.0, 29.3) (P < 0.05 versus control)., Conclusion: Plasma AT activity is severely decreased after CPB with DHCA. Our data suggest that the administration of coagulation factor components without AT repletion may lead to excessive thrombin generation, which clinically, may potentially lead to a hypercoagulable state.
- Published
- 2008
- Full Text
- View/download PDF
39. Antithrombin affects hemostatic response to recombinant activated factor VII in factor VIII deficient plasma.
- Author
-
Szlam F, Taketomi T, Sheppard CA, Kempton CL, Levy JH, and Tanaka KA
- Subjects
- Blood Coagulation Tests, Humans, In Vitro Techniques, Time Factors, Antithrombins deficiency, Coagulants pharmacology, Factor VIIa pharmacology, Hemophilia A blood, Hemostasis drug effects, Recombinant Proteins pharmacology, Thrombin metabolism
- Abstract
Background: Thromboembolic complications can occur with recombinant activated factor VII (rFVIIa) treatment in trauma and surgical patients but they are infrequent in hemophiliacs. Bleeding diathesis in these conditions is often attributed to reduced thrombin generation, which may be improved with rFVIIa. Normally, thrombin that diffuses from local vascular injury sites is quickly inactivated by antithrombin (AT). Evaluating the influence of AT levels on thrombin generation in hypocoagulable FVIII-deficient plasma would be a simple approach to better understand how procoagulant stimuli, such as rFVIIa, might result in postoperative thrombotic complications. We hypothesize that reduced AT concentrations would increase the procoagulant effects of rFVIIa in FVIII-deficient plasma., Methods: Thrombin generation was evaluated in vitro in FVIII-deficient and AT/FVIII-deficient plasma using thrombelastography and a thrombin generation assay (Thrombinoscope). The effect of added rFVIIa on these variables was evaluated., Results: Delayed thrombus formation based on thrombelastography in FVIII-deficient plasma was predictably reversed by rFVIIa. Improved thrombus formation and responses to rFVIIa were observed when AT levels were 20%-50% of normal. Thrombin generation in FVIII-deficient plasma increased in an inverse relationship to AT levels. Supplemental rFVIIa decreased the lag time of thrombin generation but not the amount of thrombin generated., Conclusions: Using FVIII-deficient plasma as a model of reduced thrombin generation, we demonstrate that low AT levels enhance in vitro hemostatic responses to rFVIIa. Reduced AT levels in trauma and surgical patients with normal or increased FVIII levels may be considered potentially prothrombotic. Monitoring of AT levels during rFVIIa therapy may thus reduce thrombotic complications in nonhemophiliacs.
- Published
- 2008
- Full Text
- View/download PDF
40. Improved clot formation by combined administration of activated factor VII (NovoSeven) and fibrinogen (Haemocomplettan P).
- Author
-
Tanaka KA, Taketomi T, Szlam F, Calatzis A, and Levy JH
- Subjects
- Blood Coagulation Tests, Cardiopulmonary Bypass, Coagulants therapeutic use, Drug Therapy, Combination, Factor VIIa therapeutic use, Fibrinogen administration & dosage, Humans, Postoperative Hemorrhage blood, Recombinant Proteins administration & dosage, Recombinant Proteins pharmacology, Time Factors, Cardiac Surgical Procedures, Coagulants pharmacology, Factor VIIa pharmacology, Fibrinogen pharmacology, Fibrinogen therapeutic use, Hemostasis drug effects, Postoperative Hemorrhage drug therapy, Recombinant Proteins therapeutic use
- Abstract
Background: Recombinant activated factor VII (rFVIIa) is increasingly used for treating refractory bleeding after cardiac surgery. However, hemostasis also depends on coagulation factors, including fibrinogen, which stabilizes platelet plugs at sites of vascular injury. We compared the hemostatic effects of rFVIIa, fibrinogen, or their combination., Methods: Blood samples were obtained from 12 volunteers and from 7 patients after cardiopulmonary bypass (CPB). The in vitro effects of rFVIIa (1.5 microg/mL), fibrinogen (100 mg/dL), and the combination were evaluated under simulated coagulopathy in volunteer plasma using heparin (0.1 U/mL) or tissue plasminogen activator (0.1 microg/mL). Hemostatic interventions were compared using thromboelastometry, which measures clotting time (CT, s), angle of thrombus formation, and maximal clot firmness (MCF, mm). The Thrombinoscope was used to quantitate thrombin generation after addition of fibrinogen and/or rFVIIa., Results: In heparinized volunteer plasma, rFVIIa shortened CT (1st and 3rd quartiles) from 663 (522-736) to 435 (397-531) s, but it did not affect MCF. Fibrinogen increased MCF from 26.0 (24.4-26.7) to 30.5 (26.3-31.5) mm without affecting CT. The combination of rFVIIa and fibrinogen in heparinized samples was most effective in improving CT to 359 (324-522) s and MCF to 29 (27.8-31.0) mm. In tissue plasminogen activator-treated volunteer plasma, fibrinolysis increased by more than 45% by the addition of rFVIIa. After CPB, both CT and MCF were most improved with coadministration of rFVIIa and fibrinogen. Thrombinoscope evaluation demonstrated that rFVIIa decreased the lag time and increased peak thrombin generation, whereas fibrinogen had no effect., Conclusion: The onset of fibrin formation and thrombin generation were shortened after rFVIIa addition, but fibrin clot strength was only increased after fibrinogen supplementation. In vitro clot formation was most improved by using both rFVIIa and fibrinogen in whole blood after CPB.
- Published
- 2008
- Full Text
- View/download PDF
41. Anaphylaxis during cardiac surgery: implications for clinicians.
- Author
-
Levy JH and Adkinson NF Jr
- Subjects
- Anaphylaxis diagnosis, Anaphylaxis etiology, Cardiac Surgical Procedures instrumentation, Environmental Exposure adverse effects, Environmental Exposure prevention & control, Humans, Intraoperative Complications diagnosis, Intraoperative Complications etiology, Practice Guidelines as Topic standards, Anaphylaxis prevention & control, Cardiac Surgical Procedures adverse effects, Intraoperative Complications prevention & control, Physicians standards
- Abstract
During surgery, patients are exposed to multiple foreign substances including anesthetic drugs, antibiotics, blood products, heparin, polypeptides (aprotinin, latex, and protamine), and intravascular volume expanders, which have the potential to produce life-threatening allergic reactions termed "anaphylaxis." The hallmark of perioperative anaphylaxis is acute cardiovascular and pulmonary dysfunction. Patients undergoing cardiac surgery have extensive monitoring that permits rapid recognition and treatment when anaphylaxis occurs. Initial, smaller doses of drugs, often called test doses, administered before the therapeutic dose may produce anaphylaxis, and so clinicians need to be prepared to treat reactions if they occur. Institution of cardiopulmonary bypass for hemodynamically unstable patients can be a life-saving maneuver, and should be considered in patients with refractory cardiovascular dysfunction. Arginine vasopressin should also be considered for patients with vasodilatory shock. In this review, we focus on recent concepts in understanding the incidence and management approaches for patients at risk for anaphylaxis in the operating room setting, with an emphasis on cardiac surgical patients.
- Published
- 2008
- Full Text
- View/download PDF
42. Clevidipine effectively and rapidly controls blood pressure preoperatively in cardiac surgery patients: the results of the randomized, placebo-controlled efficacy study of clevidipine assessing its preoperative antihypertensive effect in cardiac surgery-1.
- Author
-
Levy JH, Mancao MY, Gitter R, Kereiakes DJ, Grigore AM, Aronson S, and Newman MF
- Subjects
- Aged, Double-Blind Method, Female, Humans, Male, Middle Aged, Treatment Outcome, Vasodilator Agents therapeutic use, Antihypertensive Agents therapeutic use, Blood Pressure drug effects, Calcium Channel Blockers therapeutic use, Cardiac Surgical Procedures, Hypertension drug therapy, Preoperative Care, Pyridines therapeutic use
- Abstract
Background: Clevidipine is an ultrashort-acting, third-generation IV dihydropyridine calcium channel blocker that exerts rapid and titratable arterial blood pressure reduction, with fast termination of effect due to metabolism by blood and tissue esterases. As an arterial-selective vasodilator, clevidipine reduces peripheral vascular resistance directly, without dilating the venous capacitance bed. In this randomized, double-blind, placebo-controlled multicenter trial we evaluated the efficacy and tolerability of clevidipine in treating preoperative hypertension., Methods: One-hundred-fifty-two patients scheduled for cardiac surgery with current or recent hypertension were randomized to receive clevidipine or placebo preoperatively. One-hundred-five patients met postrandomization entrance criteria (systolic blood pressure [SBP] > or =160 mm Hg after inserting an arterial catheter) for reduction by > or =15% from baseline in SBP. The patients thus received infusions of clevidipine (0.4-8.0 microg x kg(-1) x min(-1)) or 20% lipid emulsion (placebo) for at least 30 min. Treatment failure was defined as failure to reduce SBP by > or =15% from baseline or discontinuance of drug for any reason., Results: Patients treated with clevidipine demonstrated a 92.5% rate of treatment success and a significantly lower rate of treatment failure (7.5%, 4 of 53) than patients receiving placebo (82.7%, 43 of 52; P < 0.0001). Clevidipine achieved target blood pressures (SBP reduced by > or =15%) at a median of 6.0 min (95% confidence interval 6-8 min). A modest increase in heart rate from baseline occurred during clevidipine administration. Adverse events for each treatment group were similar., Conclusions: Clevidipine was effective in rapidly decreasing blood pressure preoperatively to targeted blood pressure levels and was well tolerated in patients scheduled for cardiac surgery.
- Published
- 2007
- Full Text
- View/download PDF
43. Thrombin generation assay and viscoelastic coagulation monitors demonstrate differences in the mode of thrombin inhibition between unfractionated heparin and bivalirudin.
- Author
-
Tanaka KA, Szlam F, Sun HY, Taketomi T, and Levy JH
- Subjects
- Dose-Response Relationship, Drug, Humans, In Vitro Techniques, Peptide Fragments biosynthesis, Prothrombin biosynthesis, Recombinant Proteins pharmacology, Thrombelastography, Thrombin antagonists & inhibitors, Anticoagulants pharmacology, Antithrombins pharmacology, Blood Viscosity drug effects, Heparin pharmacology, Hirudins pharmacology, Peptide Fragments pharmacology, Thrombin biosynthesis
- Abstract
Background: Coagulation tests, such as activated partial thromboplastin time and activated clotting time, are used to monitor the effects of unfractionated heparin and the direct thrombin inhibitor, bivalirudin. These tests reflect only the initial phase of blood clotting, when <5% of thrombin has been formed. In this study, we sought to determine if similar increases in activated partial thromboplastin time or activated clotting time due to heparin or bivalirudin would reflect the same degree of inhibition of thrombin formation., Methods: Thrombin formation was evaluated in platelet-poor plasma activated in the presence of heparin (0-5 U/mL) or bivalirudin (0-30 microg/mL) using a thrombin generation assay (Thrombinoscope). Prothrombin activation was measured by prothrombin fragment 1.2 (F1.2) formation. Thrombus formation was further evaluated in kaolin-activated whole blood samples containing heparin (1.5 or 2.5 U/mL) or bivalirudin (12.5 or 25 microg/mL) using Sonoclot and thromboelastography., Results: Based on the Thrombinoscope results, increasing concentrations of bivalirudin and heparin progressively delayed the onset of thrombin formation, but only heparin dose-dependently decreased the amount of thrombin generated. Heparin and bivalirudin delayed the onset of F1.2 formation, but there was no difference in peak F1.2 levels between bivalirudin and non-anticoagulated samples (206 +/- 28.2 vs 182 +/- 23.9 nmol/L, P = 0.09). In heparinized samples, F1.2 levels were significantly lower (75.7 +/- 29.8 nmol/L, P < 0.05) than controls. Heparin and bivalirudin prolonged the onset of clotting on viscoelastic monitors, but only heparin decreased the rate of thrombus formation., Conclusion: Thrombus formation kinetics differs between heparin and bivalirudin despite similar prolongation of clotting test values.
- Published
- 2007
- Full Text
- View/download PDF
44. Fibrinogen and bleeding: old molecule--new ideas.
- Author
-
Nielsen VG and Levy JH
- Subjects
- Blood Coagulation Disorders therapy, Blood Loss, Surgical prevention & control, Colloids, Humans, Hydroxyethyl Starch Derivatives administration & dosage, Plasma Substitutes administration & dosage, Thrombelastography, Blood Coagulation Disorders etiology, Fibrinogen therapeutic use, Hemodilution adverse effects, Plasma Substitutes adverse effects
- Published
- 2007
- Full Text
- View/download PDF
45. Reducing thrombotic complications in the perioperative setting: an update on heparin-induced thrombocytopenia.
- Author
-
Levy JH, Tanaka KA, and Hursting MJ
- Subjects
- Anticoagulants immunology, Cardiac Surgical Procedures adverse effects, Diagnostic Tests, Routine, Drug Monitoring, Heparin immunology, Humans, Perioperative Care, Practice Guidelines as Topic, Thrombocytopenia chemically induced, Thrombocytopenia complications, Thrombocytopenia diagnosis, Thrombocytopenia immunology, Thromboembolism etiology, Thromboembolism immunology, Thrombosis etiology, Thrombosis immunology, Time Factors, Treatment Outcome, Antibodies blood, Anticoagulants adverse effects, Heparin adverse effects, Surgical Procedures, Operative adverse effects, Thrombocytopenia drug therapy, Thromboembolism prevention & control, Thrombosis prevention & control
- Abstract
Heparins are widely used in the perioperative setting. Immune heparin-induced thrombocytopenia (HIT) is a serious, antibody-mediated complication of heparin therapy that occurs in approximately 0.5%-5% of patients treated with heparin for at least 5 days. An extremely prothrombotic disorder, HIT confers significant risks of thrombosis and devastating consequences on affected patients: approximately 38%-76% develop thrombosis, approximately 10% with thrombosis require limb amputation, and approximately 20%-30% die within a month. HIT antibodies are transient and typically disappear within 3 mo. In patients with lingering antibodies, however, re-exposure to heparin can be catastrophic. In the perioperative setting, heightened awareness is important for the prompt recognition, diagnosis, and treatment of HIT. HIT should be considered if the platelet count decreases 50% and/or thrombosis occurs 5-14 days after starting heparin, with other diagnoses excluded. On strong clinical suspicion of HIT, heparin should be discontinued and a parenteral alternative anticoagulant initiated, even before laboratory confirmation of HIT is obtained. Subsequent laboratory test results may help with the decision to continue with nonheparin therapy or switch back to heparin. Heparin avoidance in patients with current or previous HIT is feasible in most clinical situations, except perhaps in cardiovascular surgery. If the surgery cannot be delayed until HIT antibodies have disappeared, intraoperative alternative anticoagulation is recommended.
- Published
- 2007
- Full Text
- View/download PDF
46. What is blood and what is not? Caring for the Jehovah's Witness patient undergoing cardiac surgery.
- Author
-
Sniecinski R and Levy JH
- Subjects
- Blood Coagulation Factors therapeutic use, Blood Transfusion methods, Humans, Immunoglobulins therapeutic use, Informed Consent, Patient Education as Topic, Physician-Patient Relations, Practice Guidelines as Topic, Serum Albumin therapeutic use, United States, Blood Loss, Surgical prevention & control, Blood Proteins therapeutic use, Cardiac Surgical Procedures, Jehovah's Witnesses, Patient Acceptance of Health Care, Religion and Medicine
- Published
- 2007
- Full Text
- View/download PDF
47. Coagulopathy after cardiopulmonary bypass in Jehovah's Witness patients: management of two cases using fractionated components and factor VIIa.
- Author
-
Sniecinski RM, Chen EP, Levy JH, Szlam F, and Tanaka KA
- Subjects
- Adult, Anticoagulants therapeutic use, Antithrombins therapeutic use, Aortic Aneurysm surgery, Factor VIII therapeutic use, Fibrinogen therapeutic use, Humans, Informed Consent, Middle Aged, Physician-Patient Relations, Recombinant Proteins therapeutic use, United States, Blood Loss, Surgical prevention & control, Cardiopulmonary Bypass, Coagulants therapeutic use, Factor VIIa therapeutic use, Jehovah's Witnesses, Patient Acceptance of Health Care, Religion and Medicine
- Abstract
Background: Changes in the Jehovah's Witness (JW) blood refusal policy now give members the personal choice to accept certain processed fractions of blood, such as factor concentrates and cryoprecipitate., Methods: Two JW patients undergoing complex aortic surgery who developed severe microvascular bleeding after prolonged use of cardiopulmonary bypass were treated with recombinant activated factor VII, cryoprecipitate, and antithrombin concentrate., Results: Cardiopulmonary bypass-induced coagulopathy was successfully treated, allowing chest closure without evidence of thrombotic complications., Conclusions: Processed blood fractions can be a valuable adjuvant to drugs when treating bleeding in JW patients.
- Published
- 2007
- Full Text
- View/download PDF
48. A phase II, double-blind, placebo-controlled, ascending-dose study of Eritoran (E5564), a lipid A antagonist, in patients undergoing cardiac surgery with cardiopulmonary bypass.
- Author
-
Bennett-Guerrero E, Grocott HP, Levy JH, Stierer KA, Hogue CW, Cheung AT, Newman MF, Carter AA, Rossignol DP, and Collard CD
- Subjects
- Aged, Cardiac Surgical Procedures, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Female, Humans, Lipid A administration & dosage, Lipid A blood, Male, Middle Aged, Postoperative Care, Postoperative Complications epidemiology, Postoperative Complications prevention & control, Prospective Studies, Cardiopulmonary Bypass, Lipid A analogs & derivatives, Lipid A antagonists & inhibitors
- Abstract
Background: Lipid A, the toxic moiety of endotoxin, is linked to multiple complications after cardiac surgery, including fever, vasodilation, and pulmonary and renal dysfunction. The lipid A antagonist eritoran (or E5564) prevents endotoxin-induced systemic inflammation in animals and humans. In this study we assessed the safety of eritoran administration in patients undergoing cardiac surgery and obtained preliminary efficacy data for the prophylaxis of endotoxin-mediated surgical complications., Methods: A double-blind, randomized, ascending-dose, placebo-controlled study was conducted at nine hospitals. Patients undergoing coronary artery bypass graft and/or cardiac valvular surgery with cardiopulmonary bypass were enrolled. Patients received a 4-h infusion of placebo (n = 78) vs 2 mg (n = 24), 12 mg (n = 26), or 28 mg (n = 24) of eritoran initiated approximately 1 h before cardiopulmonary bypass., Results: No significant safety concerns were identified with continuous safety monitoring, and enrollment continued to the highest prespecified dose (28 mg). No statistically significant differences were observed in most variables related to systemic inflammation or organ dysfunction/injury., Conclusions: This Phase II safety study suggests that the administration of the novel lipid A antagonist, eritoran, is not associated with overt toxicity in cardiac surgical patients. Blocking lipid A with eritoran does not appear to confer any clear benefit to elective cardiac surgical patients.
- Published
- 2007
- Full Text
- View/download PDF
49. Full-dose aprotinin use in coronary artery bypass graft surgery: an analysis of perioperative pharmacotherapy and patient outcomes.
- Author
-
Royston D, Levy JH, Fitch J, Dietrich W, Body SC, Murkin JM, Spiess BD, and Nadel A
- Subjects
- Aged, Cerebrovascular Disorders epidemiology, Cerebrovascular Disorders prevention & control, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Prospective Studies, Randomized Controlled Trials as Topic, Retrospective Studies, Treatment Outcome, Aprotinin administration & dosage, Coronary Artery Bypass, Perioperative Care, Postoperative Complications epidemiology, Postoperative Complications prevention & control
- Abstract
Background: Inappropriate activation of hemostasis and inflammation may contribute to postoperative morbidity and mortality. The serine protease inhibitor, aprotinin, has been shown to prevent tissue and organ injury in laboratory and animal studies. In this retrospective analysis, we evaluated the relationship of aprotinin therapy with organ dysfunction in humans undergoing coronary artery bypass graft surgery (CABG)., Methods: Data from prospective randomized, double-blind, placebo-controlled studies evaluating the safety and efficacy of full-dose aprotinin (2 million KIU load, 2 million KIU pump prime, and 0.5 million KIU/h continuous infusion) to reduce blood loss and transfusion requirements in patients undergoing CABG (placebo, n = 861; aprotinin, n = 862) were examined retrospectively. Primary end-points were death, adverse cerebrovascular outcome, myocardial infarction (MI), and pharmacological interventions (inotropic drugs, vasopressors, and antiarrhythmics)., Results: Univariate analysis showed that relative to placebo, full-dose aprotinin therapy was associated with significant effects on the incidence of adverse cerebrovascular outcome (odds ratio [OR] 0.42, 95% confidence interval [CI] 0.19-0.93; P = 0.03) and use of inotropic drugs (OR 0.79, 95% CI 0.65-0.97; P = 0.02), vasopressors (OR 0.74, 95% CI 0.61-0.90; P < 0.01), and antiarrhythmics (OR 0.79, 95% CI 0.65-0.96; P = 0.02), but not death (OR = 1.00, 95% CI 0.54-1.85; P = 1.0) or MI (OR 0.92, 95% CI 0.64-1.31; P = 0.6). Multivariate analysis confirmed results of univariate analysis., Conclusions: This retrospective analysis of data collected from prospective, randomized, placebo-controlled studies in CABG shows that full-dose aprotinin use was associated with a lower risk of adverse cerebrovascular outcomes and a reduced need for use of vasoactive drugs; the risk of death and perioperative MI was not affected by aprotinin therapy.
- Published
- 2006
- Full Text
- View/download PDF
50. The effects of platelet count on clot retraction and tissue plasminogen activator-induced fibrinolysis on thrombelastography.
- Author
-
Katori N, Tanaka KA, Szlam F, and Levy JH
- Subjects
- Abciximab, Adenosine Diphosphate pharmacology, Antibodies, Monoclonal pharmacology, Calcium Chloride pharmacology, Fibrin metabolism, Humans, Immunoglobulin Fab Fragments pharmacology, Platelet Aggregation Inhibitors pharmacology, Platelet Glycoprotein GPIIb-IIIa Complex drug effects, Clot Retraction, Fibrinolysis drug effects, Platelet Count, Thrombelastography, Tissue Plasminogen Activator pharmacology
- Abstract
Clot retraction and fibrinolysis may present as a decrease in amplitude on thrombelastography (TEG). The former represents normal or hyperactive platelet function, and the latter represents a fibrinolytic state. It is important to distinguish clot retraction from fibrinolysis because the treatment of each condition is different. To distinguish between these phenomena, we performed TEG with platelet-poor plasma (PPP) and platelet-rich plasma (PRP) with an increasing platelet count (range, 50-1200 x 10(9)/L) with or without abciximab. Maximum amplitude (MA) and the percentage decrease of amplitude at 30 and 60 min after MA were examined for each sample. Blood samples to which tissue plasminogen activator (tPA) was added served as positive controls for fibrinolysis. Morphological changes of clots and D-dimer levels were also examined. With higher platelet counts, the percentage decrease of amplitude after MA increased significantly at 30 and 60 min, but not in the abciximab samples. Morphological changes of clots have shown clot retraction in PRP, but not in PPP or PRP pretreated with abciximab. D-dimer levels increased only in samples to which tPA was added, but not in native PPP or PRP samples. In conclusion, we have shown that the decrease in amplitude at 30 and 60 min can be due to platelet-mediated clot retraction and can be attenuated by sample pretreatment with abciximab, which interrupts platelet-fibrin(ogen) binding.
- Published
- 2005
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.